12.63
-1.71%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jiangsu GDK Biotechnology Co
Its shares trade on Shanghai under the ticker 688670.SS. It has been listed since 2 August 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥113.2m and a net loss of CN¥173.5m. At that date it held total assets of CN¥1.42bn and shareholders' equity of CN¥1.10bn.
Jiangsu gdk Biotechnology Co., Ltd. engages in the research and development, production, and sale of human vaccines. The company is headquartered in Taizhou, Jiangsu. The company went IPO on 2021-08-02. The Company’s main product is a tetravalent influenza virus split vaccine, which is mainly used to prevent influenza caused by two influenza A virus strains and two influenza B virus strains. The firm's research products also include a variety of human vaccines for the prevention of epidemic colds, rabies, chickenpox, shingles, and pneumonia. The firm distributes its service within the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Aug 2021
- Employees
- 474
- Website
- gdkbio.com ↗
Leadership
Pay as last reported
- Mr. Jun YuChairman of the Board, since 2015
- Mr. Jianhui ZhangGeneral Manager
- Mr. Jian'guo XiaDeputy General Manager, Director, since 2015
- Mr. Bin SongDeputy General Manager
- Mr. Honggang TengDeputy General Manager
- Mr. Guoxiong TianDeputy General Manager
- Mr. Luhua XiaDeputy General Manager
- Mr. Jin ZhouSecretary of the Board
- Mr. Shenqian NieDirector
- Mr. Liangbin ZhangDirector
- Mr. Jianqiang GuanIndependent Director
- Ms. Rong ShaoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Jiangsu GDK Biotechnology's tetravalent influenza vaccine prevents four virus strains effectively.
- The company's domestic market distribution ensures strong local presence and customer trust.
- With 474 employees, the firm maintains a focused R&D team for vaccine innovation.
Weaknesses
- The company's reliance on a single product line limits diversification opportunities.
- Lack of international market presence restricts global expansion potential.
- Limited employee count may hinder rapid scaling of production and R&D efforts.
Opportunities
- Growing demand for influenza vaccines in China presents significant market potential.
- Expanding product portfolio to include pneumonia and shingles vaccines can increase market share.
- Increasing government investment in healthcare infrastructure supports biotech growth.
Threats
- Regulatory changes in China's healthcare sector could impact vaccine approval processes.
- Competition from domestic biotech firms may intensify as the market grows.
- Economic downturns might reduce public health spending and vaccine demand.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.